Inventors:
Christopher James Bungard - Lansdale PA, US
James J. Perkins - Churchville PA, US
Jesse J. Manikowski - Norristown PA, US
Pablo de Leon - Philadelphia PA, US
Robert S. Meissner - Schwenksville PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/4439, C07D 401/10, C07D 231/54, A61P 41/00, A61P 35/02, A61P 37/00, A61P 3/10, A61P 3/04, A61P 3/00, A61P 1/00, A61P 19/02, A61P 37/08, A61P 11/00, A61P 11/06, A61P 21/00, A61P 31/14, A61P 29/00, A61P 17/06, A61P 17/00, A61P 17/10, A61P 31/18, A61P 35/00, A61P 25/00, A61P 25/24, A61P 25/18, A61P 25/20, A61P 25/22, C07D 401/04, A61K 31/416
US Classification:
514338, 514406, 5462757, 5483565
Abstract:
The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.